OncoPath: Intelligent Clinical Pathway Decision Support Tool for Pre-Authorization Documentation in Non-Small Cell Lung Cancer Treatment
OncoPath: Intelligent Clinical Pathway Decision Support Tool for Pre-Authorization Documentation in Non-Small Cell Lung Cancer Treatment
批准号:
10325551
负责人:
Sharon Hensley Alford
金额:
$39.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-01 至 2022-08-31
关键词:
AddressAlgorithmsAuthorization documentationAutomobile DrivingBusinessesCancer PatientCharacteristicsChestClinicalClinical Decision Support SystemsClinical PathwaysCodeCommunicationComplexDataDecision MakingDevelopmentDocumentationGoalsGraphGuidelinesHealth Care CostsHealth systemIntelligenceIntuitionLibrariesLocationMalignant NeoplasmsManualsMapsMedical Care CostsMedical HistoryMetadataModelingNational Comprehensive Cancer NetworkNew YorkNon-Small-Cell Lung CarcinomaOncologistOncologyPaperPathway interactionsPatient-Focused OutcomesPatientsPhasePhysiciansProcessProductionRunningSavingsSelection for TreatmentsSmall Business Innovation Research GrantSocietiesTechnologyTestingThoracic OncologyTimeTreatment EfficacyUpdateValidationVisualVisualizationbasecancer therapyclinical decision supportcloud basedcostdigitalefficacy outcomeshealth planimprovedinnovationinsightmathematical methodsmathematical modelopen sourceoptimal treatmentspaymentprototypesoftware as a servicesupport toolstooltreatment guidelinestreatment planningtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Abstract
In a real-world clinical setting, busy oncologists lack the time for investigative case analysis across all feasible
treatment options, frequently updated treatment guidelines and payor specific requirements. This results in sub-
optimal decision making, incomplete pre-authorization (pre-auth) documentation, and problems with
reimbursement. Overall, this increases medical costs and payment deficits within oncology. For example, pre-
auth inefficiencies are estimated to add $83,000 a year per physician to healthcare costs, which is $1.1 billion
annually in oncology alone. To devise a treatment plan, oncologists reference National Comprehensive Cancer
Network Guidelines® (NCCN), other clinical society standards, and payor specific requirements in the context
of a patient’s medical history, tumor characteristics, and phase of treatment. One of the most used oncology
treatment guidelines referenced by oncologists and adhered to by most payors is the National Comprehensive
Cancer Network (NCCN) Guidelines®. These guidelines are presented as a schema that span 100s of pages.
A technology driven clinical decision support (CDS) system could be employed to address the need to
streamline treatment guideline analysis, payor rules review, and treatment decision documentation for
reduced overall cost to oncology practices. This proposal focuses on developing an innovative and first-of-
a-kind technology for CDS using non-small cell lung cancer (NSCLC) as the initial test case and incorporating
NCCN Guidelines, general payor specific requirements and patient data overlaid to compute feasible treatment
pathways. The team proposes the following Phase I Specific Aims:
Aim 1: Develop a graph-based mathematical model and visual presentation of NSCLC NCCN treatment
guidelines with generalized payor specific requirements. Develop a visually interactive graph-based
representation of NCCN Guidelines®. Modeling guidelines as a visual graph (nodes and arcs) will enable
oncologists to identify the optimal treatment pathway for their patients.
Aim 2: Build an analytics engine that highlights the NCCN graph model with feasible treatment options
given the patient’s case details and common payor requirements. Use an opensource tool to create
synthetic patient data and common payor constraints with an oncologist and health plan experts. Develop a
library of graph traversal algorithms to overlay and visualize the patient data in a visual user interface.
Aim 3: Execute, validate and test a proof-of-concept CDS workflow using OncoPath. Run the complete
end-to-end CDS workflow with documentation of patient details, NCCN guideline, payor requirements and
treatment decision using synthetic patient data and payor constraints generated in Aim 2.
OncoPath will enable an efficient, oncologist-friendly approach to treatment decisions and documentation,
subsequently benefitting the patient and decreasing oncology cost. Phase II will deploy a real-time instance of
OncoPath in a single thoracic oncology practice for integrated workflow and time savings validation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VIPCare: Virtual Predictive Care workflow with integrated surveillance for optimal care protocol selection and management in at-risk prostate cancer patients
-
批准号:10758350
-
项目类别:
-
资助金额:$40.65万
-
财政年份:2023
-
负责人:Sharon Hensley Alford
-
依托单位:
海外基金